Company profile

Oviva

Chronic Disease Management & Digital Therapeutics

Company profile

About Oviva

Oviva is Europe's leading digital health provider for weight-related conditions, making evidence-based care accessible to everyone who needs it—reimbursed, at scale, and proven. Founded in 2014 by Kai Eberhardt and Manuel Baumann, the company has significantly improved the lives of more than 1 million patients across Germany, the UK, and Switzerland, backed by 100+ peer-reviewed publications. Oviva's AI-enabled care combines a medical-device-certified app with clinical teams of doctors, dietitians, and behavioural specialists. The platform provides personalised dietary advice combined with unique digital tools to help patients change their habits and improve their health long-term. The company's approach is reimbursed as a certified DiGA (Digital Health Application) in Germany, delivered in partnership with the NHS in the UK, and integrated into Swiss public healthcare. The company treats obesity, hypertension, and type 2 diabetes, expanding further to become the long-term partner for chronic care in Europe. Oviva's services include digital Tier 3 Weight Management, NHS Diabetes Prevention Programme, diabetes remission services, and virtual clinics offering medical support therapy. With over 420 experienced dietitians, psychologists, and doctors, Oviva maintains a 97% recommendation rate from patients. The company operates across multiple European markets with offices in Zurich, Altendorf, London, Berlin, Potsdam, and Warsaw.

Company description Oviva official website

Primary marketChronic Disease Management & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Oviva?

Claim this profile to manage Company information and connect with the Health AI Central audience.

Claim this listing

01 · Operating footprint

Where the Company operates

Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.

Clinical focus

  • High cholesterol
  • Hypertension
  • Obesity
  • PCOS
  • Type 2 diabetes
  • Weight-related conditions

Who it serves

  • Government healthcare
  • Health Systems
  • Payers
  • Providers

Deployment & integration

Deployment information is currently being developed.

Recorded integration context: ePA 3.0 (electronic patient record), RISE Technology, Telematikinfrastruktur (Germany).

Geographic context

MarketsGermany · Poland (operations) · Switzerland · United Kingdom
Company sourceOfficial website

Company milestones

Platform expansion

Surpassed 1 million patients treated (July 2025). Secured €200 million Series D funding (January 2026). Hypertension DiGA approved by BfArM (January 2026). Reached 124,700 prescriptions in 2024, ranking #1 in DiGA market. Launched virtual Oviva Clinics in UK and Switzerland (2024). Expanded to weight loss medication support services.

Partnerships

Recorded partners

  • 30,000+ doctors (as of 2025)
  • 5,000+ referring doctors across Europe
  • Multiple German health insurers
  • NHS (United Kingdom)
  • Swiss public healthcare system

02 · Flagship portfolio

Products, workflows, and platform capabilities

Selected source-backed Company products and the available commercial context.

No source-backed Company products are currently listed.

03 · Research intelligence

Research Intelligence evidence

Publications, preprints, clinical validation, and regulatory records in Evidence Position order.

04 · Company-reported outcomes

Outcomes and case studies

Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.

97% patient recommendation rate

Overall patient satisfaction

50% reduction in workplace sick days

Study of 700 NHS patients

Significant reduction in healthcare visits

NHS patient study

Significant weight reduction

AMODA clinical trial

Blood pressure and weight reduction

Dual-action hypertension DiGA

Long-term weight loss maintenance

Clinical study showing sustained results

05 · Leadership

Leadership team

Leadership profiles and professional links from the current Company record.

No active leadership profiles are currently listed.

06 · Company updates

Updates from Oviva

Recent articles published on Oviva's official website.

07 · HAIC coverage

Coverage and analysis

Health AI Central reporting that mentions this Company.

No HAIC coverage is currently linked to this Company.

08 · Official presence

Company sources and channels

Curated official destinations from the active Company record.

09 · Market pathway

Additional Companies in this Market

Other active Companies in the same market, selected alphabetically from the HAIC directory.

Market context

Chronic Disease Management & Digital Therapeutics

Companies using AI and digital health tools to help patients manage chronic conditions through digital therapeutics, gamified health management, and AI-powered coaching. Covers management of all chronic diseases including diabetes, hypertension, COPD, heart disease, and multi-condition platforms. Includes continuous glucose monitoring (CGM) systems with AI analytics and insulin optimization algorithms.

Explore the full market directory or compare this Company with additional active profiles.

View all Companies in this market

10 · Pro research

Coming soon

Expanded Company research is in development.

Health AI Central Pro · Coming Soon

Deeper Company research is coming soon.

Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.

ResearchEvidence analysis

Linked research, clinical, and regulatory source pathways.

CompanyTechnical context

Expanded product, deployment, integration, and partnership research.

MethodSource & review record

Record-level provenance and review context.

Coming Soon